Tranexamic acidClinical trial
= hydroquinone
melasma score at 12 weeks — fewer side effects
3% tranexamic acid against 3% hydroquinone + dexamethasone, one side of the face each: both reduced melasma, no significant difference — and significantly fewer side effects on the tranexamic side.
Ebrahimi & Naeini · J. Research in Medical Sciences · 2014
Double-blind, split-face · 50 people
Studied at 3%. In NUXI: 4%, Face Serum
Read the study on PubMed →
NiacinamideClinical + lab
4 weeks
to less hyperpigmentation than the base cream
A 5% niacinamide moisturiser significantly decreased hyperpigmentation and increased skin lightness against its base; in the lab it cut pigment transfer by 35–68%.
Hakozaki et al. · British Journal of Dermatology · 2002
Paired clinical trials + lab models · 138 people
In NUXI: 10% in the Face Serum, 5% in the Cream
Read the study on PubMed →
NiacinamideClinical trial
2 weeks
to lower sebum output than placebo
2% niacinamide significantly lowered the rate the skin produces oil after two and four weeks against a placebo; surface oil fell by week six in a second group.
Draelos et al. · J. Cosmetic & Laser Therapy · 2006
Double-blind, placebo-controlled · 130 people
Studied at 2%. In NUXI: 10%, Face Serum
Read the study on PubMed →
Alpha arbutinLab study
−60%
melanin in a 3D human skin model
Alpha arbutin reduced melanin to 40% of the untreated model, and lowered the activity of tyrosinase, without harming the cells.
Sugimoto et al. · Biological & Pharmaceutical Bulletin · 2004
Lab study · run by the ingredient’s maker
In NUXI: alpha arbutin 2%, Face Serum and Cream
Read the study on PubMed →